Incorporating Prognostic Gene Expression Profile Assays into the Management of Cutaneous Melanoma: An Expert Consensus Panel

Zakria, Danny; Brownstone, Nicholas; Berman, Brian M.; Ceilley, Roger I.; Goldenberg, Gary; Lebwohl, Mark; Litchman, Graham; Siegel, Daniel M.

doi:10.25251/skin.7.1.1

Cited by 5 publications

(5 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to reach consensus for each statement, a modified Delphi process was utilized [ 27 ]. This process requires supermajority approval for adoption of a recommendation through multiple rounds of real-time voting and is a regularly utilized method to create expert recommendations in dermatology [ 28 – 31 ]. All panel experts involved in the study are authors of the manuscript and were informed of the study’s objectives.…”

Section: Methodsmentioning

confidence: 99%

The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel

Burshtein,

Shah,

Zakria

et al. 2024

Dermatol Ther (Heidelb)

Self Cite

View full text Add to dashboard Cite

Introduction Psoriasis is a chronic inflammatory condition affecting the skin, joints, and several other organ systems with significant disease burden. Bimekizumab is the first monoclonal antibody targeting both interleukin (IL)-17A and interleukin-17F and has demonstrated efficacy for treating moderate to severe psoriasis. Limited guidelines exist for incorporating this drug into clinical practice. The purpose of this study was for a panel of experts in psoriasis management to synthesize current literature and provide consensus statements with guidance on use of bimekizumab. Methods A comprehensive literature search of PubMed, Scopus, and Google Scholar was completed for English-language original research articles on the use of bimekizumab for moderate to severe psoriasis and psoriatic arthritis. A panel of nine dermatologists with significant expertise in treatment of psoriasis gathered to review the articles and create consensus statements on this new medication. A modified Delphi process was used to approve each statement and a strength of recommendation was assigned using Strength of Recommendation Taxonomy criteria. Results The literature search produced 102 articles that met criteria. A thorough screening of the studies for relevance to the research question resulted in 19 articles. These were distributed to all panelists for review prior to a roundtable discussion. The panel unanimously voted to adopt 14 consensus statements and recommendations, 12 of which were given a strength of “A”, one of which was given a strength of “B”, and one of which was given a strength of “C”. Conclusion Bimekizumab results in rapid and long-lasting clinical improvement for patients with moderate to severe plaque psoriasis and psoriatic arthritis. It has demonstrated superior efficacy when compared to several other biologics. The safety profile is consistent with other biologics, except for an increased incidence of oropharyngeal candidiasis.

show abstract

Section: Methodsmentioning

confidence: 99%

The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel

Burshtein,

Shah,

Zakria

et al. 2024

Dermatol Ther (Heidelb)

Self Cite

View full text Add to dashboard Cite

show abstract

“…16 This process requires a supermajority vote to adopt a statement via multiple rounds of real-time voting and has been frequently utilized to create expert recommendations in dermatology. [17][18][19][20] Of note, a level 2 or 3 designation does not necessarily indicate a poor study but is requisite for retrospective studies or review articles.…”

Section: Development Of Consensus Statementsmentioning

confidence: 99%

The Role of Field Cancerization in Selecting Therapies for Actinic Keratosis: An Expert Consensus Panel

Zakria,

Shah,

Burshtein

et al. 2024

J of Skin

View full text Add to dashboard Cite

Background: Actinic keratosis is a very common disease that affects over 40 million people in the United States. In addition to the clinically visible lesion, patients may present with surrounding field cancerization based on their history of ultraviolet exposure. While lesion-directed therapy such as cryosurgery can effectively treat individual actinic keratoses it does not treat subclinical lesions or field cancerization. Objective: To create consensus recommendations on the role of field cancerization in selecting appropriate therapy for actinic keratoses. Methods: A comprehensive literature search of PubMed, Google Scholar, and Embase was conducted using the keywords “actinic keratos*,” “treatment,” and “field cancerization” for English-language original research articles without date restrictions. Articles were included that either discussed the role of FC in treating AKs or compared various AK field therapies. The relevant articles were then distributed to a panel of nine dermatologists with significant expertise in managing AKs. Each panelist reviewed the articles and assigned them a level of evidence based on Strength of Recommendation Taxonomy (SORT) criteria. The panel then convened on to discuss the studies and develop consensus statements on the role of FC in selecting AK therapy. The panel utilized a modified Delphi process to approve the adoption of each statement and gave each one a strength of recommendation based on SORT criteria. Results: The initial literature search produced 243 articles that met search criteria. After a thorough screening of these articles for relevance to the research question, 21 articles were chosen to be reviewed by the panel and assigned a level of evidence. Of the 21 articles that were reviewed, the panel assigned level 1 evidence to three articles, level 2 evidence to six articles, and level 3 evidence to twelve articles. The panel created seven consensus statements related to AK management and FC. All seven statements received a unanimous (9/9) vote for adoption. Each of the statements was given a strength of recommendation according to sort criteria Conclusion: Field cancerization due to chronic ultraviolet exposure leads to subclinical AK lesions in addition to lesions that are clinically apparent. In order to address these lesions, field therapy is an important component of an adequate regimen and can be used in conjunction with lesion-directed therapy for optimal results.

show abstract

“…31 This process entails two-thirds supermajority approval through serial rounds of real-time voting and is a frequently utilized method to create expert recommendations in dermatology. [32][33][34][35]…”

Section: Development Of Consensus Statementsmentioning

confidence: 99%

Evaluating the Efficacy and Safety of Bimekizumab for Plaque Psoriasis and Psoriatic Arthritis: An Expert Consensus Panel Report

Zakria,

Miller,

Chao

et al. 2024

J of Skin

View full text Add to dashboard Cite

Background: While there are numerous effective therapies for psoriasis, there remains an unmet need as some patients still suffer from inadequate response with available medications. Bimekizumab is a first-in-class monoclonal antibody that inhibits both interleukin (IL)-17A and IL-17F and was recently approved by the Food and Drug Administration. The aim of this study was for a panel of experts in psoriasis management to review the available data on bimekizumab and create consensus statements on its use in clinical practice. Methods: A comprehensive literature search of PubMed, Scopus, and Google Scholar was conducted for English-language original research articles, systematic reviews, and meta-analyses discussing the safety and efficacy of bimekizumab for moderate to severe plaque psoriasis and psoriatic arthritis. A panel of nine dermatology physician assistants and one dermatology nurse practitioner with significant expertise in the management of psoriasis convened virtually on December 16, 2023, to review the studies and create recommendations for their peers on the use of bimekizumab. A modified Delphi process was implemented to reach a consensus on these statements and the Strength of Recommendation Taxonomy was used to assign each one a strength of recommendation. Results: The literature search resulted in 92 articles that met search criteria. After a thorough screening of these studies for relevance to the discussion questions, 20 articles remained and were distributed to each panelist prior to the meeting. The panel unanimously voted to adopt 10 consensus recommendations and assigned all 10 statements a strength of recommendation of “A.” Conclusion: Bimekizumab has a very high efficacy in the treatment of moderate to severe psoriasis and psoriatic arthritis. It also has a favorable safety profile that is consistent with that of other biologics, except for an increased risk of oral candidiasis.

show abstract

Incorporating Prognostic Gene Expression Profile Assays into the Management of Cutaneous Melanoma: An Expert Consensus Panel

Cited by 5 publications

References 42 publications

The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel

The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel

The Role of Field Cancerization in Selecting Therapies for Actinic Keratosis: An Expert Consensus Panel

Evaluating the Efficacy and Safety of Bimekizumab for Plaque Psoriasis and Psoriatic Arthritis: An Expert Consensus Panel Report

Contact Info

Product

Resources

About